Clinical Trial

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to investigate the routes of elimination and overall mass balance of 100 mg quemliclustat containing 75 μCi \[14C\] following a single IV infusion of \[14C\]-quemliclustat in healthy adult male participants, and to quantify total radioactivity (TRA) in plasma, whole blood, urine, and feces.
Protocol Amendment History 2 changes
critical Trial completed 2026-05-02
notable Primary completion pushed: 2026-03 -> 2026-04-06 2026-05-02
Trial Details
NCT Number NCT07364214
Lead Sponsor Arcus Biosciences, Inc.
Conditions Healthy Participants
Enrollment 8 participants
Start Date 2026-02-03
Primary Completion 2026-04-06 (estimated)
Study Completion 2026-04-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-01